Clinical trial
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Recruiting now · Phase 3 · 1 countries · Registry ID NCT07654361
What this study is about
Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calorie diet and increased physical activity. All participants will be randomized to at least 76 weeks of treatment to evaluate the effects on long term body weight changes, tolerability, and safety. In addition, the study will compare the effects between aleniglipron and placebo on blood pressure (BP), lipid parameters, patient-reported outcomes.
Basic eligibility
Full registry criteria
Treatments and study arms
Aleniglipron
Drug: aleniglipron administered orally Drug
Placebo
Drug: placebo administered orally
Primary outcomes
Study locations
71 locations were listed when this page was built. The first 40 are shown.